SynthesisRenal failure2021
Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.
Synthesis in Renal failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 7 syntheses or guidelines pooled it, 122 citations in OpenAlex.
- The role of gut microbiota in hypertension-mediated organ damage (HMOD): a systematic review.Journal of translational medicine · 2025Pooled it
- Gut Microbiome in Patients with Chronic Kidney Disease Stages 4 and 5: A Systematic Literature Review.International journal of molecular sciences · 2025Pooled it
- Clinical efficacy of probiotics in the treatment of diabetes kidney disease: a systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis.Annals of medicine · 2023Pooled it
- Alterations of the gut microbiota in the lupus nephritis: a systematic review.Renal failure · 2023Pooled it
- Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis.Renal failure · 2022Pooled it
- Specific alterations of gut microbiota in patients with membranous nephropathy: A systematic review and meta-analysis.Frontiers in physiology · 2022Pooled it
- Probiotic treatment induces changes in intestinal microbiota but does not alter SCFA levels in peritoneal dialysis patients-a randomized, placebo-controlled trial.Scientific reports · 2024Trial
- Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation.Nutrients · 2024Trial
- Curcumin Supplementation (MerivaNutrients · 2022Trial
- Gut microbiota biomarkers of chronic kidney disease progression identified by 16S rDNA sequencing and machine learning.Renal failure · 2026Article
- A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026Review
- LactuloseWorld journal of nephrology · 2026Article
- Mind the Gut: Cognitive Decline, Microbiota, and Nutrition-Related Modulators in Older Adults with Chronic Kidney Disease.Nutrients · 2026Review
- Short-Term High-Altitude Exposure Alters Pharyngeal and Gut Microbiome.Environment & health (Washington, D.C.) · 2026Article
- Gut-kidney axis: Dysbiosis and renal disease.World journal of nephrology · 2026Review
- Pediatric and adult point of view on the gut-kidney axis in CKD.Pediatric nephrology (Berlin, Germany) · 2026Review
- Analysis of gut microbiota and fecal/plasma short-chain fatty acids in non-dialysis renal anemia patients: associations with clinical parameters.Frontiers in microbiology · 2026Article
- Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products.Frontiers in pharmacology · 2026Review
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmerging evidence demonstrates that gut dysbiosis is implicated in the pathogenesis of chronic kidney disease (CKD) with underlying mechanisms involving mucosal and/or systematic immunity or metabolic disorders. However, the profile of gut microbiota in patients with CKD has not been completely explored.
methodsDatabases from their date of inception to 31 March 2020 were systematically searched for case-control or cross-sectional studies comparing the gut microbial profiles in adult patients with CKD or end-stage renal disease (ESRD) with those in healthy controls. Quantitative analysis of alterations in gut microbial profiles was conducted.
resultsTwenty-five studies with a total of 1436 CKD patients and 918 healthy controls were included. The present study supports the increased abundance of, phylum
conclusionsSpecific alterations of gut microbial parameters in patients with CKD were identified. However, a full picture of the gut microbiota could not be drawn from the data due to the differences in methodology, and qualitative and incomplete reporting of different studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.